Comparison · NCT03369236-85ace968
Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) vs Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period): Participants With Significant Improvement In eGFR Relative To Baseline At Week 52
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) vs Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period): Participants With Significant Improvement In eGFR Relative To Baseline At Week 52. Trial comparisons, record NCT03369236-85ace968. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03369236-85ace968
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.434 | wilson | |
| Risk in group 2 | 0 | 0 | 0.434 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.434 | 0.434 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) | Danicopan was administered at a starting dose of 100 mg TID for the first 2 weeks, then dosage was to be increased to 200 mg TID for the remainder of the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID. | 0 | 5 | OG000 |
| Group 2 | Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) | Placebo was administered TID during the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID. | 0 | 5 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants With Significant Improvement In eGFR Relative To Baseline At Week 52
- Description
- Significant improvement relative to baseline was defined as a ≥ 20% increase from baseline in eGFR.
- Time frame
- Baseline, Week 52
- Population
- All participants who received at least 1 dose of study drug and had analyzable data at the specified timepoints.
Source ClinicalTrials.gov
Trial
- Title
- A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
- NCT number
- NCT03369236
- Phases
- PHASE2
- Conditions
- C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
- Interventions
- Danicopan, Placebo
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Results first posted
- 2021-11-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03369236?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03369236-85ace968